Cancer Immunotherapy Market by Application (Colorectal, Lung, Breast, Prostate, Melanoma, Head & Neck), Type (Cancer Vaccines, Monoclonal Antibodies, Immunomodulators, Check Point Inhibitor), End User (Clinics, Hospital) – 2020 to 2025

$3,850.00$5,850.00

AVAIL 20% DISCOUNT ON PURCHASE OF ANY REPORT
Published on: March 23, 2020
Clear
SKU: GMS-2065 Category:

The global immunotherpay cancer market is expected to hit USD 173.2 billion by 2025, rising over the forecast period at a CAGR of 11.78%. This rise can be attributed to factors such as increased target therapy adoption over traditional therapy, biosimilar development, increased demand for mAbs, high cancer prevalence.

Cancer Immunotherapy Market by Application (Colorectal, Lung, Breast, Prostate, Melanoma, Head & Neck), Type (Cancer Vaccines, Monoclonal Antibodies, Immunomodulators, Check Point Inhibitor), End User (Clinics, Hospital) - 2020 to 2025 1

Cancer Immunotherapy Market by Application (Colorectal, Lung, Breast, Prostate, Melanoma, Head & Neck), Type (Cancer Vaccines, Monoclonal Antibodies, Immunomodulators, Check Point Inhibitor), End User (Clinics, Hospital) - 2020 to 2025 2

Cancer Immunotherapy Market by Application (Colorectal, Lung, Breast, Prostate, Melanoma, Head & Neck), Type (Cancer Vaccines, Monoclonal Antibodies, Immunomodulators, Check Point Inhibitor), End User (Clinics, Hospital) - 2020 to 2025 3

Cancer Immunotherapy Market by Application (Colorectal, Lung, Breast, Prostate, Melanoma, Head & Neck), Type (Cancer Vaccines, Monoclonal Antibodies, Immunomodulators, Check Point Inhibitor), End User (Clinics, Hospital) - 2020 to 2025 4

Cancer Immunotherapy Market by Application (Colorectal, Lung, Breast, Prostate, Melanoma, Head & Neck), Type (Cancer Vaccines, Monoclonal Antibodies, Immunomodulators, Check Point Inhibitor), End User (Clinics, Hospital) - 2020 to 2025 5

Cancer Immunotherapy Market by Application (Colorectal, Lung, Breast, Prostate, Melanoma, Head & Neck), Type (Cancer Vaccines, Monoclonal Antibodies, Immunomodulators, Check Point Inhibitor), End User (Clinics, Hospital) - 2020 to 2025 6

Cancer Immunotherapy Market by Application (Colorectal, Lung, Breast, Prostate, Melanoma, Head & Neck), Type (Cancer Vaccines, Monoclonal Antibodies, Immunomodulators, Check Point Inhibitor), End User (Clinics, Hospital) - 2020 to 2025 7

Cancer Immunotherapy Market by Application (Colorectal, Lung, Breast, Prostate, Melanoma, Head & Neck), Type (Cancer Vaccines, Monoclonal Antibodies, Immunomodulators, Check Point Inhibitor), End User (Clinics, Hospital) - 2020 to 2025 8

1 Global Cancer Immunotherapy Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 Global Cancer Immunotherapy Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 Global Cancer Immunotherapy Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis

5 Global Cancer Immunotherapy Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies

6 Global Cancer Immunotherapy Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes

7 Global Cancer Immunotherapy Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)

8 Global Cancer Immunotherapy Market – By Type (Market Size – & million/billion)
8.1 Monoclonal Antibodies
8.2 Cancer Vaccines
8.3 Checkpoint Inhibitors
8.4 Immunomodulators

9 Global Cancer Immunotherapy Market – By Deployment
9.1 Lung Cancer
9.2 Breast Cancer
9.3 Head and Neck Cancer
9.4 Prostate Cancer
9.5 Colorectal Cancer
9.6 Others

10 Global Cancer Immunotherapy Market – By End-User
10.1 Hospitals
10.2 Clinics
10.3 Others

11 Global Cancer Immunotherapy Market – By Geography (Market Size – & million/billion)
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 U.K
11.3.2 Germany
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 South Korea
11.4.5 Rest of APAC
11.5 Rest of the World
11.5.1 South America
11.5.2 Middle East
11.5.3 Africa

12 Global Cancer Immunotherapy Market – Entropy
12.1 New product launches
12.2 M&A’s, collaborations, JVs and partnerships

13 Global Cancer Immunotherapy Market Company Profile (Key Players)
13.1 Market Share, Company Revenue, Products, M&A, Developments
13.2 Amgen Inc.
13.3 Astrazeneca
13.4 Bristol-Myers Squibb
13.5 ELI Lilly and Company
13.6 F. Hoffmann-La Roche Ltd
13.7 Bayer AG
13.8 Pfizer
13.9 Janssen Global Services
13.10 Merck
13.11 Novartis
13.12 Company 11 & more

14 Global Cancer Immunotherapy Market – Appendix
14.1 Sources
14.2 Abbreviations